PMID- 32850379
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Deoxyshikonin Inhibits Viability and Glycolysis by Suppressing the Akt/mTOR 
      Pathway in Acute Myeloid Leukemia Cells.
PG  - 1253
LID - 10.3389/fonc.2020.01253 [doi]
LID - 1253
AB  - Deoxyshikonin was reported to exhibit an anti-tumor effect in colorectal cancer. 
      However, no studies are available to illustrate the effect of deoxyshikonin on 
      acute myeloid leukemia (AML). The effects of deoxyshikonin on viability, 
      apoptosis, caspase-3/7 activity, and cytochrome (Cyt) C expression were evaluated 
      by Cell Counting Kit-8 assay, flow cytometry analysis, caspase-3/7 activity 
      assay, and western blot analysis, respectively. Glucose consumption and lactate 
      production were measured to determine the glycolysis level. The expression of 
      pyruvate kinase M2 (PKM2) was detected by quantitative real-time polymerase chain 
      reaction and western blot analysis. The results showed that deoxyshikonin 
      inhibited cell viability and increased the apoptotic rate, the caspase-3/7 
      activity, and the Cyt C protein level in AML cells in a dose-dependent manner. 
      Additionally, deoxyshikonin concentration-dependently decreased glucose 
      consumption, lactate production, and PKM2 expression in AML cells. Deoxyshikonin 
      inactivated the protein kinase B (Akt)/mammalian target of the rapamycin (mTOR) 
      pathway. The activation of the Akt/mTOR pathway reversed the effects of 
      deoxyshikonin on viability, apoptosis, and glycolysis in AML cells. In 
      conclusion, deoxyshikonin dampened the viability and the glycolysis of AML cells 
      by suppressing PKM2 via inactivation of the Akt/mTOR signaling.
CI  - Copyright (c) 2020 Wu, Zhao and Chen.
FAU - Wu, Huijuan
AU  - Wu H
AD  - Telemedicine and Connected Health Center, Huaihe Hospital of Henan University, 
      Kaifeng, China.
FAU - Zhao, Hongmian
AU  - Zhao H
AD  - Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, China.
FAU - Chen, Li
AU  - Chen L
AD  - Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, China.
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7427633
OTO - NOTNLM
OT  - PKM2
OT  - acute myeloid leukemia
OT  - deoxyshikonin
OT  - glycolysis
OT  - the Akt/mTOR signaling
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
PMCR- 2020/01/01
CRDT- 2020/08/28 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.01253 [doi]
PST - epublish
SO  - Front Oncol. 2020 Aug 7;10:1253. doi: 10.3389/fonc.2020.01253. eCollection 2020.